Excelra Achieves Leader Status in Everest Group's PEAK Matrix® Assessment for IT Services in Pharmaceutical Research and Development

Excelra Recognized as a Leader in Everest Group's PEAK Matrix® Assessment 2026

Excelra, a global data and informatics solutions company specializing in life sciences, has proudly been named a Leader in the Everest Group's prestigious PEAK Matrix® Assessment 2026. This evaluation focuses on IT services catered specifically to the pharmaceutical research and development sector. A total of 34 service providers were assessed based on their market impact, vision, and capabilities, following a rigorous RFI process that included customer references.

According to the Everest Group, this recognition is a testament to Excelra's robust combination of curated data, scientific AI, and expert knowledge in the field. Excelra’s flagship product, GOSTAR®, offers an impressive 37 million data points dedicated to bioactivity, specifically designed to harness the power of AI and machine learning. The company’s scientific AI solutions are built upon high-quality scientific data and are tailored for use in life sciences R&D.

In recent times, Excelra has expanded its on-ground offerings through strategic mergers and acquisitions, enhancing its team of scientific advisors and improving proximity to its global clientele. Furthermore, Excelra has developed a strong partner ecosystem that includes leading cloud service providers and laboratory informatics technology platforms.

Durga Ambati, VP at the Everest Group, commented on Excelra's standing in the industry: "Pharmaceutical companies prioritize partners that combine deep scientific and functional expertise with strong capabilities in data, AI, and platforms. Excelra stands out with its proprietary scientific datasets, including GOSTAR, which supports AI-driven drug discovery through SAR analysis, as well as its verticalized scientific AI solutions that cover multimodal data analysis, scientific knowledge extraction, and regulatory information. These strengths have positioned Excelra as a Leader in our PEAK Matrix® Assessment 2026 for IT services in pharmaceutical R&D."

Anandbir Brar, CEO of Excelra, expressed his thoughts on this significant achievement, stating, "Science comes first, and this is a conviction we have never compromised on. This recognition reaffirms that belief. In pharmaceutical R&D, the depth of science is now as valuable as the size of the company. As AI becomes increasingly integral to R&D, it's crucial that partners comprehend both the science and the technology. I am grateful to our clients for entrusting us with their critical work, and I take pride in our teams whose expertise has made this possible."

For further insights and detailed information regarding Excelra's performance in the Everest Group evaluation, interested parties can visit their official website.

About Excelra

Excelra's engineering teams instill confidence in AI-powered research and development by combining AI-capable data and platforms, connected laboratory informatics, and multi-omics expertise to transform the complexity of R&D into informed decisions. Their motto is scientific-led, data-driven, and outcome-focused. To learn more, visit www.excelra.com.

About the Everest Group

The Everest Group is a leading research firm that supports business leaders in making informed decisions. They guide clients through the market's current challenges and fortify their strategies by applying context-driven solutions tailored to individual situations. More information can be found at www.everestgrp.com.